RxDoctor Payments Data

Arpeta Gupta, MD

Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1760624688

Payments from drug & device makers

$31,870in general payments, 2019–2025

Across 568 payments — averaging $56.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$21K
  • Novo Nordisk$1K
  • Lilly USA, LLC$816
  • Amgen$773
  • Abbott$747
  • Sanofi-aventis U.S. LLC$649
  • plus $6K from 40 others

What the payments were for

  • Speaking & faculty fees$17,62055%
  • Travel & lodging$2,3597%
  • Food & beverage$11,69637%
  • Education$760%
  • Gifts$1190%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,870 in reported general payments places this provider in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$107,665
Medicare patients
302
Services billed
2,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KorlymMifepristone13$517,596
OzempicSemaglutide241$359,429
MounjaroTirzepatide185$207,893
RybelsusSemaglutide49$75,361
JardianceEmpagliflozin48$66,360
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/725$40,918
Evenity (2 Syringes)Romosozumab-Aqqg15$37,292
Tresiba Flextouch U-100Insulin Degludec48$26,089
TrulicityDulaglutide23$25,448
JanuviaSitagliptin Phosphate23$19,172
FarxigaDapagliflozin Propanediol14$12,548
Fiasp FlextouchInsulin Aspart (Niacinamide)13$11,957
Gvoke Hypopen 2-PackGlucagon17$10,112
Insulin Lispro Kwikpen U-100Insulin Lispro30$7,912
Nano 2nd Gen Pen NeedlePen Needle, Diabetic39$6,511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Corcept TherapeuticsKorlym$21,388$517,59613 claims
Novo NordiskOzempic, Rybelsus$1,307$434,791290 claims
Lilly USA, LLCMounjaro, Trulicity$816$233,341208 claims
Boehringer IngelheimJardiance$244$66,36048 claims
AmgenEvenity (2 Syringes)$773$37,29215 claims
MerckJanuvia$32$19,17223 claims
AstraZenecaFarxiga$243$12,54814 claims
AbbVieSynthroid$283$5,05267 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$34$2,138246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →